세계의 액체 생검 시장(제6판)

Liquid biopsies have emerged as a minimally invasive diagnostic tool, analyzing tumor-derived materials circulating in biological fluids to offer valuable information for cancer diagnosis, treatment, and monitoring. While tissue biopsies and imaging techniques remain standard in solid tumor diagnosis, liquid biopsies present an alternative or complementary approach, addressing some of the limitations and risks associated with traditional methods.

Key applications of liquid biopsy testing in clinical oncology include:

1. Early Detection and Diagnosis/Screening:

• Identifying cancer at an early stage.

2. Alternative Testing Method:

• When tissue biopsy is challenging or impossible.
• When the primary site of metastatic disease is unknown.

3. Therapy Personalization and Monitoring:

• Molecular characterization to select optimal therapy.
• Monitoring treatment efficacy and adjusting therapy in case of resistance.

4. Disease Monitoring:

• Observing disease progression, tumor evolution, residual disease.
• Early detection of recurrence.

5. Prognosis of Disease:

• Assessing the likely course and outcome of the disease.

The liquid biopsy market is experiencing significant changes, and “ The Worldwide Market for Liquid Biopsy, 6^th Edition ” from Kalorama Information provides an in-depth assessment of the market opportunity from 2023 to 2028. The brand new market research report covers various aspects, including market segmentation by region, different types of liquid biopsy (CTC-based, ctDNA-based, EV and Exosome-based, Multi-Analyte-based, and Other Analytes), and cancer types.

Key Market Segments:

• By Region:
  • North America
  • Europe
  • Asia
  • Rest of World

• By Type of Liquid Biopsy:
  • CTC-based Liquid Biopsy
  • ctDNA-based Liquid Biopsy
  • EV and Exosome-based Liquid Biopsy
  • Multi-Analyte-based Liquid Biopsy
  • Other Analytes Liquid Biopsy

• By Type of Cancer:
  • Breast
  • Lung
  • Colorectal
  • Ovarian
  • Prostate
  • Pan-Cancer
  • Other Cancers

• R&D and Selected Tests:
  • Selected ctDNA-based Liquid Biopsy Tests in Development
  • Selected CTC-based Liquid Biopsy Tests in 2023
  • Selected Liquid Biopsy Tests Assessing Multiple Analytes in 2023

The growing acceptance of liquid biopsy, even during the 6^th pandemic, underscores its increasing significance in clinical diagnostics. Liquid biopsy's potential in combination with other technologies further contributes to its expanding applications and market growth.

The report also profiles key companies in the liquid biopsy market. These include:

Top of Form

Bottom of Form

Table of Contents

Chapter One: Executive Summary

• Introduction
• Liquid Biopsy Technologies
• Industry Structure
• Liquid Biopsy Market Revenues and Forecast
  • Figure 1-1: Market for Liquid Biopsy, 2023-2028 ($M)
  • Figure 1-2: Global Liquid Biopsy Market Share, by Geographic Region, 2023 (%)
  • Table 1-1: Global Liquid Biopsy Market by Geographic Region, 2023-2028 ($M)

Chapter Two: Liquid Biopsy Technologies

• Introduction
  • Table 2-1: Comparison of Tissue and Liquid Biopsy
• Current Major Liquid Biopsy Technologies
  • Table 2-2: Advantages and Limitations of Major Liquid Biopsy Technologies

Chapter Three: Circulating Tumor DNA (ctDNA) Liquid Biopsy

• Introduction
• Advantages and Limitations of ctDNA in Liquid Biopsy
• Current ctDNA-based Liquid Biopsy Tests
  • Table 3-1: Selected ctDNA-based Liquid Biopsy Tests, 2023
• Biocartis
• Biodesix
• CellMax Life
• Circulogene
• Diacarta
• Foundation Medicine (Roche)
• Guardant Health
• Inivata (Neogenomics)
• LungLife AI
• Myriad Genetics
• NeoGenomics
• OncoDNA
• Personal Genomic Diagnostics (LabCorp)
• QIAGEN
• Resolution Biosciences (Exact Sciences)
• Roche Diagnostics
• Sysmex-Inostics
• Tempus
• ctDNA-based Liquid Biopsy Tests in Development
• Table 3-2: Selected ctDNA-based Liquid Biopsy Tests in Development, 2023
  • Exact Sciences
• Freenome
• GRAIL

Chapter Four: Circulating Tumor Cells (CTCs) Liquid Biopsy

• Introduction
• Challenges in the Development of CTC-based Liquid Biopsy Tests
• CTC-based Liquid Biopsy Tests
  • Table 4-1: Selected CTC-based Liquid Biopsy Tests, 2023
• Adaptive Biotechnologies
• ANGLE
• CellMax Life
• Epic Sciences
• GILUPI
• LungLife AI
• Menarini-Silicon Biosystems
• QIAGEN
• Selected CTC-based Liquid Biopsy Tests in Development
  • Table 4-2: Selected CTC-based Liquid Biopsy Tests in Development, 2023
• Epic Sciences
• Liquid Biotech USA

Chapter Five: Extracellular Vesicles and Other Liquid Biopsy

• Introduction
• Liquid Biopsy Tests Based on Extracellular Vesicles / Other Analytes
  • Table 5-1: Selected Liquid Biopsy Tests based on Extracellular Vesicles / Other Analytes, 2023
• Aspira Women's Health (formerly Vermillion)
• Biodesix
• Exosome Diagnostics
• Hologic
• MDxHealth
• Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development
  • Table 5-2: Selected Extracellular Vesicle/Other Analyte-based Liquid Biopsy Tests in Development, 2023
• Circulogene
• OncoCyte
• Resolution Biosciences (Exact Sciences)
• VolitionRx

Chapter Six: Multi-Analyte Liquid Biopsy Tests

• Introduction
• Liquid Biopsy Tests Based on Multiple Analytes
  • Table 6-1: Selected Liquid Biopsy Tests That Assess Multiple Analytes, 2023
• Biodesix
• Foundation Medicine (Roche)
• LungLife AI
• NeoGenomics
• OncoDNA
• Multiple Analyte-based Liquid Biopsy Tests in Development
  • Table 6-2: Selected Multi Analyte-based Liquid Biopsy Tests in Development, 2023
• Exact Sciences
• Freenome
• GRAIL
• LungLife AI

Chapter Seven: Liquid Biopsy Tests for Research Use Only

• Introduction
• Liquid Biopsy Tests for Research Use Only
  • Table 7-1: Selected Liquid Biopsy Tests for Research Use Only, 2023
• Agena Bioscience
• DiaCarta
• Exosome Diagnostics
• Guardant Health
• Natera
• QIAGEN

Chapter Eight: Liquid Biopsy Industry Analysis

• Introduction
• Tiers of Competition
  • Table 8-1: Selected Participants in the Liquid Biopsy Market, 2023
• Competitive Factors
• Significant Market Trends
  • Table 8-2: Significant Trends in the Liquid Biopsy Market, 2023
• Personalized Medicine
• Increasing Global Life Expectancy
• New Liquid Biopsy Products
• Increasing Accessibility of Genetic Testing
• Regulatory Hurdles
• Third-Party Payor Coverage
• Demonstrated Clinical Utility
• Incidence Rates of Specific Cancers
• Competitors No Longer in the Liquid Biopsy Market
  • Table 8-3: Summary of Companies That Have Exited the Liquid Biopsy Market

Chapter Nine: Liquid Biopsy Market

• Market Overview
  • Table 9-1: Global Liquid Biopsy Diagnostics Market Estimate, by Region, 2023-2028 ($M)
  • Figure 1-2: Global Liquid Biopsy Market, by Geographic Region, 2023 ($M)
  • Figure 9-2: Global Liquid Biopsy Diagnostics Market Estimated Share, by Region, 2023 (%)
• Market Forecast
  • Figure 9-3: Global Liquid Biopsy Market Forecast, by Region (North America, Europe, Asia Pacific, Rest of World), 2023-2028 ($M)

Chapter Ten: Market by Analyte

• Circulating Tumor DNA
• Market Overview
• Applications
• Technologies
• Specimens
• Revenue Forecast
  • Table 10-1: Global Liquid Biopsy Market for ctDNA, 2023-2028 ($M)
• Circulating Tumor Cells
• Market Overview
• Applications
• Technologies
• Specimens
• Revenue Forecast
  • Table 10-2: Global Liquid Biopsy Market for CTCs, 2023-2028 ($M)
• Extracellular Vesicles and Other Analytes
• Market Overview
• Applications
• Technologies
• Specimens
• Revenue Forecast
  • Table 10-3: Global Liquid Biopsy Market for Extracellular Vesicles, 2023-2028 ($M)
• Multiple Analytes
• Market Overview
• Revenue Forecast
  • Table 10-4: Global Liquid Biopsy Market for Multiple Analytes, 2023-2028 ($M)

Chapter Eleven: Market by Application

• Therapy Guidance and Monitoring
• Market Overview
• Revenue Forecast
  • Table 11-1: Liquid Therapy for Therapy Guidance, 2023-2028 ($M)
• Diagnosis/Screening
• Market Overview
• Revenue Forecast
  • Table 11-2: Global Liquid Biopsy Market for Diagnosis and Screening, 2023-2028 ($M)
• Disease Prognosis
• Market Overview
• Revenue Forecast
  • Table 11-3: Global Liquid Biopsy Market for Disease Prognosis, 2023-2028 ($M)

Chapter Twelve: Market by Cancer Type

• Breast Cancer
• Market Overview
• Revenue Forecast
  • Table 12-1: Global Liquid Biopsy Market for Breast Cancer, 2023-2028 ($M)
• Colorectal Cancer
• Market Overview
• Revenue Forecast
  • Table 12-2: Global Liquid Biopsy Market for Colorectal Cancer, 2023-2028 ($M)
• Lung Cancer
• Market Overview
• Revenue Forecast
  • Table 12-3: Global Liquid Biopsy Market for Lung Cancer, 2023-2028 ($M)
• Ovarian Cancer
• Market Overview
• Revenue Forecast
  • Table 12-4: Global Liquid Biopsy Market for Ovarian Cancer, 2023-2028 ($M)
• Prostate Cancer
• Market Overview
• Revenue Forecast
  • Table 12-5: Global Liquid Biopsy Market for Prostate Cancer, 2023-2028 ($M)
• Other Cancers
• Market Overview
• Revenue Forecast
  • Table 12-6: Global Liquid Biopsy Market for Other Cancers, 2023-2028 ($M)
• Pan-Cancer Tests
• Market Overview
• Revenue Forecast
  • Table 12-7: Global Liquid Biopsy Market for Pan-Cancer Testing, 2023-2028 ($M)

Chapter Thirteen: Company Profiles

• Companies in the Market
  • Table 13-1 Companies in the Liquid Biopsy Market

• Adaptive Biotechnologies
  • Company Overview
• Agena Bioscience, Inc.
  • Company Overview
• ANGLE, plc
  • Company Overview
• Aspira Women's Health
  • Company Overview
• Biocartis Group NV
  • Company Overview
• Biocept, Inc. (closed)
  • Company Overview
• Biodesix
  • Company Overview
• CellMax Life
  • Company Overview
• Circulogene
  • Company Overview
• DiaCarta, Inc.
  • Company Overview
• Epic Sciences
  • Company Overview
• Epigenomics AG (closed)
  • Company Overview
• Exact Sciences
  • Company Overview
• Exosome Diagnostics, Inc.
  • Company Overview
• Foundation Medicine, Inc. (Roche)
  • Company Overview
• Freenome, Inc.
  • Company Overview
• GILUPI GmbH
  • Company Overview
• GRAIL (Illumina)
  • Company Overview
• Guardant Health, Inc.
  • Company Overview
• Hologic
  • Company Overview
• LungLife AI (formerly Cynvenio Biosystems)
  • Company Overview
  • Company Overview
• Menarini-Silicon Biosystems, Spa
  • Company Overview
• Myriad Genetics, Inc.
  • Company Overview
• Natera, Inc.
  • Company Overview
• NeoGenomics Laboratories, Inc.
  • Company Overview
• Oncocyte Corporation
  • Company Overview
• OncoDNA S.A.
  • Company Overview
• Personal Genome Diagnostics
  • Company Overview
• QIAGEN N.V.
  • Company Overview
• Cell-free DNA Technologies
• CTC Technologies
• Exosome and miRNA Technologies
• Resolution Biosciences (Agilent)
  • Company Overview
• Roche Diagnostics
  • Company Overview
• Sysmex-Inostics, Inc.
  • Company Overview
• Tempus
  • Company Overview
• VolitionRx
  • Company Overview